Mass Spectrometry-based Immune Profiling in Autoimmune Diseases

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorPeking University People's Hospital

About this trial

Based on mass spectrometry flow method, this study analyzed the typing of new T, B, NK and DC cell subsets in peripheral blood of common autoimmune diseases and their correlation with disease activity, aiming at establishing an early screening and diagnosis model of autoimmune diseases.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Male or female, and aged 18-70 at the time of screening interview (inclusive).

The diagnosis of each disease meets the following standards - Systemic lupus erythematosus: 1997 ACR lupus classification standard

Behcet's disease: 2014 ICBD Behcet's disease classification standard

ANCA-associated vasculitis: 1990 American College of Rheumatology Classification Standard

Disqualifiers

None

Trial population

The patients are in a state of disease activity and do not use biological agents.

Trial design

Design model

Cohort

Time perspective

Cross-sectional

Treatments tested in this trial

Not listed

Trial groups

500 Participants
are grouped into 1 trial group
Group A: The patients with active autoimmune diseases

Trial outcomes

Primary outcomes

1

proportion of immune cell subsets in peripheral blood.

Immune cell subsets include T cell, B cell, NK cell, Treg cell, Tfh cell, CLA+Treg cell, Tfr cell, Th1 cell, Th2 cell, Th17 cell and some unnamed cell subsets.

Time frame
through study completion, an average of 1 year

Secondary outcomes

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Peking University People's Hospital

Lead sponsor

National Natural Science Foundation of China

Collaborator

Zhejiang PuLuoTing Health Technology Co., Ltd.

Collaborator

This trial is not recruiting at the moment. You can still explore other options: